What is the trade name of tremelimumab?

Tremelimumab/tremelimumab was initially obtained in October 2022 in the United States in October 2022 by the U.S. Food and Drug Administration (FDA), and Sold under the brand name imjudo, it contains tremelimumab, a human monoclonal antibody directed against the activity of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which is expressed on the surface of T lymphocytes. By blocking the activity of CTLA-4, tremelimumab helps T cells activate, trigger an immune response to cancer, and promote cancer cell death.